MRI contrast developer Epix Pharmaceuticals of Lexington, MA, said that its request for continued listing on the Nasdaq Global Market has been granted.
The ruling by the Nasdaq Listing Qualifications Panel is subject to the condition that Epix file a current report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) by May 11, attesting to its compliance with SEC requirements of maintaining shareholders' equity of at least $10 million or a minimum market value of listed securities of $50 million.
Related Reading
Epix gets FDA OK for Vasovist, December 23, 2008
Epix reduces its workforce, October 23, 2008
Epix to form technology advisory board, August 14, 2008
Epix's Q2 results show boosted revenues, August 7, 2008
Epix secures equity financing, August 5, 2008
Copyright © 2009 AuntMinnie.com
